Edwards Lifesciences (NYSE:EW) Shares Gap Up After Strong Earnings

Shares of Edwards Lifesciences Corporation (NYSE:EW) gapped up prior to trading on Friday following a better than expected earnings announcement. The stock had previously closed at $83.82, but opened at $88.00. Edwards Lifesciences shares last traded at $86.8420, with a volume of 1,411,581 shares.

The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.85% and a net margin of 15.43%.The business had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the prior year, the business posted $0.67 earnings per share. Edwards Lifesciences’s revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS.

Key Headlines Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards Lifesciences beat Q2 estimates on both earnings and revenue, with sales rising 13.6% year over year to $1.74 billion, helped by strong demand for heart-valve products and growing adoption of mitral and tricuspid therapies.
• Positive Sentiment: The company raised the low end of its full-year revenue outlook to $6.6 billion-$6.9 billion and also lifted its TAVR growth guidance, signaling management confidence in continued momentum.
• Positive Sentiment: Analysts turned more constructive after the report: JPMorgan raised its price target to $105 and kept an overweight rating, while Leerink upgraded the stock to outperform with a $101 target.
• Positive Sentiment: Commentary from Wall Street framed the quarter as evidence that Edwards remains a top medtech growth story, with its core TAVR franchise and newer structural heart therapies driving the upside.
• Neutral Sentiment: The company’s updated Q3 and full-year EPS guidance was broadly in line with expectations, suggesting the current move is being driven more by sales strength and sentiment than by a major earnings surprise.

Analyst Upgrades and Downgrades

Several brokerages have commented on EW. Royal Bank Of Canada raised their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. BTIG Research upped their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Truist Financial raised their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. Finally, Barclays reiterated an “overweight” rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average price target of $99.55.

Insiders Place Their Bets

In other news, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel J. Lippis sold 619 shares of the stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $91.70, for a total transaction of $56,762.30. Following the completion of the sale, the vice president directly owned 40,034 shares of the company’s stock, valued at $3,671,117.80. This trade represents a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 45,577 shares of company stock worth $3,855,527. 0.31% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in EW. Norges Bank acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after acquiring an additional 4,108,270 shares during the last quarter. Viking Global Investors LP acquired a new position in shares of Edwards Lifesciences in the third quarter worth $238,688,000. Marshall Wace LLP raised its holdings in shares of Edwards Lifesciences by 66.1% during the fourth quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after acquiring an additional 2,359,128 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Edwards Lifesciences by 132.4% during the first quarter. Bank of America Corp DE now owns 3,883,419 shares of the medical research company’s stock worth $310,984,000 after acquiring an additional 2,212,208 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 1.4%

The firm has a market capitalization of $47.60 billion, a PE ratio of 47.51, a price-to-earnings-growth ratio of 2.07 and a beta of 0.86. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The company has a fifty day moving average of $87.73 and a 200-day moving average of $83.88.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.